Clinical Reviews in Allergy & Immunology

, Volume 33, Issue 1–2, pp 134–143 | Cite as

Chronic Urticaria: Recent Advances

Article

Abstract

Chronic urticaria is an umbrella term, which encompasses physical urticarias, chronic “idiopathic” urticaria and urticarial vasculitis. It is important to recognize patients with physical urticarias as the investigation and treatment differs in important ways from patients with idiopathic chronic urticaria or urticarial vasculitis. Although relatively uncommon, urticarial vasculitis is an important diagnosis to make and requires histological confirmation by biopsy. Underlying systemic disease and systemic involvement, especially of the kidneys, should be sought. It is now recognized that chronic “idiopathic” urticaria includes a subset with an autoimmune basis caused by circulating autoantibodies against the high affinity IgE receptor (FceR1) and less commonly against IgE. Although the autologous serum skin test has been proven useful in prompting search for and characterization of circulating wheal-producing factors in chronic urticaria, its specificity as a screening test for presence of functional anti-FceR1 is low, and confirmation by demonstration of histamine-releasing activity in the patient’s serum must be the benchmark test in establishing this diagnosis. Improved screening tests are being sought; for example, ability of the chronic urticaria patient’s serum to evoke expression of CD 203c on donor human basophils is showing some promise. The strong association between autoimmune thyroid disease and autoimmune urticaria is also an area of ongoing research. Drug treatment continues to be centered on the H1 antihistamines, and the newer second-generation compounds appear to be safe and effective even in off-label dosage. Use of systemic steroids should be confined to special circumstances such as tapering regimens for acute flare-ups. Use of leukotriene antagonists is becoming popular, but the evidence for efficacy is conflicting. Cyclosporin is also effective and can be used in selected cases of autoimmune urticaria, and it is also effective in non-autoimmune cases, although less so.

Keywords

Urticaria Vasculitis Angioedema Autoimmune 

References

  1. 1.
    Sheldon JM, Mathews KP, Lovell RG (1954) The vexing urticaria problem : present concepts of etiology and management. J Allergy 25:525–560PubMedCrossRefGoogle Scholar
  2. 2.
    Champion RH, Roberts SOB, Carpenter RG, Roger JH (1969) Urticaria and angioedema: a review of 554 patients. Br J Dermatol 81:588–597PubMedCrossRefGoogle Scholar
  3. 3.
    Zuberbier T, Bindslev-Jensen C, Canonica W et al (2005) EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria AllergyGoogle Scholar
  4. 4.
    O’Donnell BF, Lawlor F, Simpson J et al (1997) The impact of chronic urticaria on quality of life. Br J Dermatol 136:553–556CrossRefGoogle Scholar
  5. 5.
    Sabroe RA, Seed PT, Francis DM et al (1999) Chronic idiopathic urticaria : comparison of clinical features of patients with and without anti-FcɛR1 or anti-IgE autoantibodies. J Amer Acad Dermatol 40:443–450CrossRefGoogle Scholar
  6. 6.
    O’Donnell BF, Black AK (1995) Urticarial Vasculitis Int Angiol 14:166–174Google Scholar
  7. 7.
    Black AK (2004) Physical urticarias. In: Greaves MW, Kaplan AP (eds) Urticaria and Angioedema. Marcel Dekker, NYGoogle Scholar
  8. 8.
    Grattan CEH, Boon AP, Eady RAJ, Winkelmann RK (1990) The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late phase reactions. Int Arch Allergy Immunol 93:198–204CrossRefGoogle Scholar
  9. 9.
    Frandji P et al (1998) IL-4 mRNA transcription is induced in mouse bone marrow-derived mast cells through an MHC class11-dependent signaling pathway. Eur J Immunol 28:844–855PubMedCrossRefGoogle Scholar
  10. 10.
    Michaelsson G, Juhlin L (1973) Urticaria induced by preservatives and dye additives in food and drugs. Br J Dermatol 88:525–532PubMedCrossRefGoogle Scholar
  11. 11.
    Greaves MW (2001) Chronic idiopathic urticaria and H pylori: not directly causative but could there be a link? ACI International 13:23–26Google Scholar
  12. 12.
    Rorsman H (1962) Basophilic leucopenia in different forms of urticaria. Acta Allergologica 17:168–184PubMedGoogle Scholar
  13. 13.
    Leznoff A, Sussman GL (1989) Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 84:66–71PubMedCrossRefGoogle Scholar
  14. 14.
    Hide M, Francis DM, Grattan CEH et al (1993) Autoantibodies against the high affinity IgE receptor as acause for histamine release in chronic urticaria. New Eng J Med 328:1599–1604PubMedCrossRefGoogle Scholar
  15. 15.
    Nimii N, Francis DM, Kermani F et al (1996) Dermal mast cell activation by autoantibody against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 106:1001–1006CrossRefGoogle Scholar
  16. 16.
    Fiebiger E, Maurer D, Holub H et al (1995) Autoantibodies directed against the α-chain of Fcepsilon R1; a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients. J Clin Invest 96:2606–2612PubMedGoogle Scholar
  17. 17.
    Tong LJ, Balakrishnan G, Kochan JP et al (1997) Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 99:461–465PubMedCrossRefGoogle Scholar
  18. 18.
    Soundararajan S, Kikuchi K, Joseph K, Kaplan AP (2005) Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 115:815–821PubMedCrossRefGoogle Scholar
  19. 19.
    Fiebiger E, Hammaerschmid F, Stingl G, Maurer D (1998) Anti-Fcepsilon R1 autoantibodies in autoimmune-mediated disorders. Identification of a structure function relationship. J Clin Invest 101:243–251PubMedCrossRefGoogle Scholar
  20. 20.
    Ferrer M, Nakazawa K, Kaplan AP (1999) Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 104:169–172PubMedCrossRefGoogle Scholar
  21. 21.
    Kikuchi Y, Kaplan AP (2002) A role for C5a in augmenting IgG dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 109:114–118PubMedCrossRefGoogle Scholar
  22. 22.
    Greaves MW, Plummer VM, McLaughlan P, Stanworth DR (1974) Serum and cell bound IgE in chronic urticaria. Clin Allergy 4:265–271PubMedCrossRefGoogle Scholar
  23. 23.
    Sabroe RA, Francis DM, Barr RM et al (1998) Anti-Fcepsilon R1 autoantibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 102:651–658PubMedCrossRefGoogle Scholar
  24. 24.
    Confino-Cohen R, Aharoni D, Goldberg A et al (2002) Evidence for aberrant regulation of the P21 Ras pathway in PBMCC’s of patients with chronic urticaria. J Allergy Clin Immunol 109:349–356PubMedCrossRefGoogle Scholar
  25. 25.
    Grattan CEH, Francis DM, Hide M, Greaves MW (1991) Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 21:695–704PubMedCrossRefGoogle Scholar
  26. 26.
    Sabroe RA, Poon E, Orchard GE et al (1999) Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-Fc epsilon R1 or anti-IgE autoantibodies. J Allergy Clin Immunol 103:484–493PubMedCrossRefGoogle Scholar
  27. 27.
    Grattan CEH, Wallington TB, Warin RP et al (1986) A serological mediator in chronic idiopathic urticaria—a clinical immunological and histological evaluation. Br J Dermatol 114:583–590PubMedCrossRefGoogle Scholar
  28. 28.
    Sabroe RA, Grattan CEH, Francis DM et al (1999) The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 140:446–452PubMedCrossRefGoogle Scholar
  29. 29.
    Sabroe RA, Fiebiger E, Francis DM et al (2002) Classification of anti-FcɛR1 and anti-IgE autoantibodies in chronic urticaria and correlation with disease activity. J Allergy Clin Immunol 40:492–499CrossRefGoogle Scholar
  30. 30.
    Asero R, Tedeschi A, Lorini M et al (2001) Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy 31:1105–1110PubMedCrossRefGoogle Scholar
  31. 31.
    Grattan CEH, Sabroe RA, Greaves MW (2002) Chronic urticaria. J Amer Acad Dermatol 46:645–657CrossRefGoogle Scholar
  32. 32.
    Greaves MW (2003) Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 3:363–368PubMedCrossRefGoogle Scholar
  33. 33.
    Kaplan AP (2004) Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 114:465–474PubMedCrossRefGoogle Scholar
  34. 34.
    Ferrer M, Luquin E, Kaplan AP (2003) IL-3 effect on basophils histamine release upon stimulation with chronic urticaria sera. Allergy 58:802–807PubMedCrossRefGoogle Scholar
  35. 35.
    Zweiman B, Valenzano M, Atkins PC et al (1996) Characteristics of histamine releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 98:89–98PubMedCrossRefGoogle Scholar
  36. 36.
    Ferrer M, Kinet JP, Kaplan A (1998) Comparative studies of functional and binding assays for IgG anti-Fc(epsilon) R1 alpha (alpha subunit) in chronic urticaria. J Allergy Clin Immunol 101:672–676PubMedCrossRefGoogle Scholar
  37. 37.
    Kikuchi Y, Kaplan AP (2001) Mechanisms of autoimmjune activation of basophils in chronic urticaria. J Allergy Clin Immunol 107:1056–1062PubMedCrossRefGoogle Scholar
  38. 38.
    Brunetti L, Francavilla R, Miniello VL et al (2004) High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 114:922–927PubMedCrossRefGoogle Scholar
  39. 39.
    Horn MP, Pachlopnik JM, Vogel M et al (2001) Conditional autoimmunity mediated by human natural anti-FcɛR1α autoantibodies. FASEB J 15:2268–2274PubMedCrossRefGoogle Scholar
  40. 40.
    Pachlopnik JM, Horn MP, Fux M et al (2004) Natural FcɛR1α autoantibodies may interfere with diagnostic tests for chronic urticaria. J Autoimmun 22:43–51PubMedCrossRefGoogle Scholar
  41. 41.
    Horn MP Gerster T, Ochensberger B et al (1999) Human anti-FcɛR1α autoantibodies isolated from healthy donors cross react with tetanus toxoid. Eur J Immunol 29:1139–1148PubMedCrossRefGoogle Scholar
  42. 42.
    Kozel MMA, Bossuyt PMM, Mekkes JR et al (2003) Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Amer Acad Dermatol 48:409-416CrossRefGoogle Scholar
  43. 43.
    Zuberbier T, Bindslev-Jensen C, Canonica W et al (2006) EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 61:321–331PubMedCrossRefGoogle Scholar
  44. 44.
    Soter NA (1977) Chronic urticaria as a manifestation of necrotizing venulitis. N Eng J Med 296:1440–1442CrossRefGoogle Scholar
  45. 45.
    O’Donnell BF, Francis DM, Swana GT et al (2005) Thyroid autoimmunity in chronic urticaria. Brit J Dermatol 153:331–335CrossRefGoogle Scholar
  46. 46.
    Leznoff A, Josse RG, Denberg J, Dolovich J (1983) Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 119:636–640PubMedCrossRefGoogle Scholar
  47. 47.
    Kaplan AP, Finn A (1999) Autoimmunity and the etiology of chronic urticaria. Canad J Allergy Clin Immunol 4:286–292Google Scholar
  48. 48.
    Greaves MW (2005) Antihistamines in dermatology. Skin Physiol Pharmacol 18:220–229CrossRefGoogle Scholar
  49. 49.
    Nelson HS, Reynolds R, Mason J (2000) Fexofenadine HCL is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 84:517–522PubMedCrossRefGoogle Scholar
  50. 50.
    Versten J, Volkerts, ER, Von Ostenwijck AW et al (2003) Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance and mood. J Allergy Clin Immunol 111:623–627CrossRefGoogle Scholar
  51. 51.
    Weiler J, Bloom JR, Woodworth GG et al (2000) Effects of fexofenadine, diphenhydramine and alcohol on driving performance. A randomized placebo-controlled trial in the Iowa driving simulator. Ann Int Med 132:354–363PubMedGoogle Scholar
  52. 52.
    Bleehen S, Thomas SE, Greaves MW et al (1987) Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double blind study. Br J Dermatol 117:81–88PubMedCrossRefGoogle Scholar
  53. 53.
    Sackett DL, Rosenberg WMC, Gray JA et al (1996) Evidence based medicine: what it is and what it isn’t : its about integrating individual clinical expertise and the best external evidence. Br Med J 312:71–72Google Scholar
  54. 54.
    Ellis MH (1998) Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 102:876–877PubMedCrossRefGoogle Scholar
  55. 55.
    Bagenstose SE, Levin L, Bernstein JA (2004) The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 113:134–140PubMedCrossRefGoogle Scholar
  56. 56.
    Pacor ML, Di Lorenzo G, Corrocher R (2001) Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or salicylic acid. Clin Exp Allergy 31:1607–1614PubMedCrossRefGoogle Scholar
  57. 57.
    Nettis E, Dambra P, D’Oronzio L et al (2001) Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 137:99–100PubMedGoogle Scholar
  58. 58.
    Perez C, Sanchez-Borges M (2001) Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 108:1060–1061PubMedCrossRefGoogle Scholar
  59. 59.
    Erbagci Z (2002) The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind placebo-controlled crossover. J Allergy Clin Immunol 110:484–488PubMedCrossRefGoogle Scholar
  60. 60.
    Di Lorenzo G, Pacor ML, Mansueto P et al (2004) Randomised placebo- controlled trial comparing desloratidine and montelukast in monotherapy and deslotatidine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 114:619–625PubMedCrossRefGoogle Scholar
  61. 61.
    Wechsler ME, Garbpestad E, Flier SR et al (1998) Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. J Amer Med Ass 279:455–457CrossRefGoogle Scholar
  62. 62.
    Kaplan AP (2002) Chronic urticaria and angioedema. New Eng J Med 346:175–179PubMedCrossRefGoogle Scholar
  63. 63.
    Wong E, Eftekhari N, Greaves MW, Milford Ward A (1987) Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol 116:553–556PubMedCrossRefGoogle Scholar
  64. 64.
    Parsad D, Pandhi R, Juneja A (2001) Stanozolol in chronic urticaria: results of a double blind placebo controlled trial. J Dermatol 28:299–302PubMedGoogle Scholar
  65. 65.
    Kessel A, Bamberger E, Toubi E (2005) Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open label prospective study. J Amer Acad Dermatol 52:145–148CrossRefGoogle Scholar
  66. 66.
    Grattan CEH, O’Donnell BF, Francis DM et al (2000) Randomised double blind study of cyclosporine in chronic idiopathic urticaria. Br J Dermatol 143:365–372PubMedCrossRefGoogle Scholar
  67. 67.
    O’Donnell BF, Barr RM, Black AK et al (1998) Intravenous immunoglobulin in chronic urticaria. Br J Dermatol 138:101–106PubMedCrossRefGoogle Scholar
  68. 68.
    Grattan CEH, Francis DM, Slater NGP et al (1992) Plasmapheresis for severe unremitting chronic urticaria. Lancet 339:1078–1080PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  1. 1.St Johns Institute of Dermatology, St Thomas’ HospitalLondonUK
  2. 2.London Allergy ClinicLondonUK
  3. 3.National Skin CentreSingaporeSingapore

Personalised recommendations